Crizotinib in Patients With MET-Amplified NSCLC

摘要: Abstract Introduction MET amplification is a rare, potentially actionable, primary oncogenic driver in patients with NSCLC. Methods The influence of on the clinical activity ALK, ROS1, and inhibitor, crizotinib (250 mg twice daily), was examined NSCLC (NCT00585195) who were enrolled into high (≥4 MET-to-CEP7 ratio), medium (>2.2 to Results A total 38 ratio greater than or equal 1.8 by local fluorescence situ hybridization testing received crizotinib. All response-assessable, among whom 21, 14, 3 had high, medium, low amplification, respectively. ORRs 8 21 (38.1%), 2 14 (14.3%), 1 (33.3%), median duration response 5.2, 3.8, 12.2 months, progression-free survival values 6.7, 1.9, months observed for those gene copy number 6 detected next-generation sequencing 15 19 (78.9%) analyzable patients. Of these patients, objective responses six (40%), two concurrent exon alterations. No five KRAS, BRAF, EGFR mutations. Conclusions Patients high-level, MET-amplified responded highest ORR. Use combined diagnostics other oncogenes may identify most likely respond